Pharmacologic reactivation of latent feline immunodeficiency virus ex vivo in peripheral CD4+ T-lymphocytes

Virus Research

Volumn 170, Issue 1-2, 2012, Pages 174-179

  McDonnel, Samantha J ^a   Sparger, Ellen E ^b   Luciw, Paul A ^b   Murphy, Brian G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD4 T cells; DZNep; Epigenetic; FIV; Histone deacetylase; Latency; SAHA

Indexed keywords

3 DEAZANEPLANOCIN A; BUTYRIC ACID; CD134 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; KI 67 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RNA DIRECTED DNA POLYMERASE; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EX VIVO STUDY; FELINE IMMUNODEFICIENCY VIRUS; HISTONE MODIFICATION; LATENT VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; VIRION; VIRUS REACTIVATION;

ANIMALS; CATS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTONE DEACETYLASE INHIBITORS; IMMUNODEFICIENCY VIRUS, FELINE; LEUKOCYTES, MONONUCLEAR; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84870415922     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2012.10.009     Document Type: Article

References (20)

1. Archin N.M., Espeseth A., Parker D., Cheema M., Hazuda D., Margolis D.M. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Research and Human Retroviruses 2009, 25(2):207-212.
2. Burkhard M.J., Dean G.A. Transmission and immunopathogenesis of FIV in cats as a model for HIV. Current HIV Research 2003, 1(1):15-29.
3. Contreras X., Schweneker M., Chen C.S., McCune J.M., Deeks S.G., Martin J., Peterlin B.M. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. Journal of Biological Chemistry 2009, 284(11):6782-6789.
4. Diehl L.J., Mathiason-Dubard C.K., O'Neil L.L., Obert L.A., Hoover E.A. Induction of accelerated feline immunodeficiency virus disease by acute-phase virus passage. Journal of Virology 1995, 69(10):6149-6157.
5. Douillard J.Y., Bennouna J., Vavasseur F., Deporte-Fety R., Thomare P., Giacalone F., Meflah K. Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer. Cancer Immunology, Immunotherapy 2000, 49(1):56-61.
6. Geeraert L., Kraus G., Pomerantz R.J. Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annual Review of Medicine 2008, 59:487-501.
7. Ghosh S.K., Perrine S.P., Williams R.M., Faller D.V. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood 2012, 119(4):1008-1017.
8. Kanzaki L.I., Looney D.J. Feline immunodeficiency virus: a concise review. Frontiers in Bioscience 2004, 9:370-377.
9. Kavanaugh S.M., White L.A., Kolesar J.M. Vorinostat: a novel therapy for the treatment of cutaneous T-cell lymphoma. American Journal of Health-System Pharmacy 2010, 67(10):793-797.
10. Lerner D.L., Elder J.H. Expanded host cell tropism and cytopathic properties of feline immunodeficiency virus strain PPR subsequent to passage through interleukin-2-independent T cells. Journal of Virology 2000, 74(4):1854-1863.
11. Mann B.S., Johnson J.R., Cohen M.H., Justice R., Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12(10):1247-1252.
12. Margolis D.M. Histone deacetylase inhibitors and HIV latency. Current Opinion in HIV AIDS 2011, 6(1):25-29.
13. Marks P.A., Richon V.M., Breslow R., Rifkind R.A. Histone deacetylase inhibitors as new cancer drugs. Current Opinion in Oncology 2001, 13(6):477-483.
14. McDonnel S.J., Sparger E.E., Luciw P.A., Murphy B.G. Transcriptional regulation of latent feline immunodeficiency virus in peripheral CD4+ T-lymphocytes. Viruses 2012, 4(5):878-888.
15. Mizukoshi F., Baba K., Horiuchi H., Goto-Koshino Y., Setoguchi-Mukai A., Fujino Y., Ohno K., Moore P.F., Tsujimoto H. Characterization of monocyte-derived dendritic cells from cats infected with feline immunodeficiency virus. Journal of Veterinary Medical Science 2009, 71(7):865-871.
16. Murphy B., Vapniarsky N., Hillman C., Castillo D., McDonnel S., Moore P., Luciw P.A., Sparger E.E. FIV establishes a latent infection in feline peripheral blood CD4+ T lymphocytes in vivo during the asymptomatic phase of infection. Retrovirology 2012, 9(1):12.
17. Perrine S.P., Ginder G.D., Faller D.V., Dover G.H., Ikuta T., Witkowska H.E., Cai S.P., Vichinsky E.P., Olivieri N.F. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. New England Journal of Medicine 1993, 328(2):81-86.
18. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., Pomerantz R.J. The challenge of finding a cure for HIV infection. Science 2009, 323(5919):1304-1307.
19. Shen L., Siliciano R.F. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. Journal of Allergy and Clinical Immunology 2008, 122(1):22-28.
20. Willett B.J., McMonagle E.L., Logan N., Spiller O.B., Schneider P., Hosie M.J. Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand. Journal of Virology 2007, 81(18):9665-9679.